StreetInsider.com News Articles

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: PARMAR KUSH

Fri, 12 Jun 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260612/26642258.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: PARMAR KUSH

Fri, 12 Jun 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260612/26642258.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: Chapman Gina

Fri, 12 Jun 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260612/26642085.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: Chapman Gina

Fri, 12 Jun 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260612/26642085.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: KIM PETER S

Fri, 12 Jun 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260612/26642093.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: KIM PETER S

Fri, 12 Jun 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260612/26642093.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: Radhakrishnan Maha

Fri, 12 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26641956.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: Radhakrishnan Maha

Fri, 12 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26641956.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: Thistle Mary

Fri, 12 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260612/26641883.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: Thistle Mary

Fri, 12 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260612/26641883.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: Zeiher Bernhardt G

Fri, 12 Jun 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260612/26641729.html

Form 4 Entrada Therapeutics, For: Jun 10 Filed by: Zeiher Bernhardt G

Fri, 12 Jun 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260612/26641729.html

Form 8-K Entrada Therapeutics, For: Jun 10

Wed, 10 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260610/26629881.html

Form 8-K Entrada Therapeutics, For: Jun 10

Wed, 10 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260610/26629881.html

Entrada Therapeutics (TRDA) PT Lowered to $17 at Guggenheim

Mon, 08 Jun 2026 06:51:36 -0400

Guggenheim analyst Debjit Chattopadhyay lowered the price target on Entrada Therapeutics (NASDAQ: TRDA) to $17.00 (from $20.00) while maintaining a Buy rating.

Entrada Therapeutics (TRDA) PT Lowered to $17 at Guggenheim

Fri, 05 Jun 2026 14:14:55 -0400

Guggenheim analyst Debjit Chattopadhyay lowered the price target on Entrada Therapeutics (NASDAQ: TRDA) to $17.00 (from $20.00) while maintaining a Buy rating.

Entrada Therapeutics receives approval to increase drug dose in DMD trial

Tue, 02 Jun 2026 07:03:11 -0400

Entrada Therapeutics Inc. (NASDAQ: TRDA) announced that an independent Data Monitoring Committee has recommended proceeding with Cohort 2 of its ELEVATE-45-201 study at an increased dose of 10 mg/kg, up from 5 mg/kg used in Cohort 1.

The committee reviewed safety and pharmacokinetic data from eight participants enrolled in Cohort 1 of the Phase 1/2 study evaluating ENTR-601-45 for Duchenne muscular dystrophy treatment. The study targets participants with confirmed mutations in the DMD gene amenable to exon 45 skipping.

Participants from Cohort 1 have progressed to the open-label Phase 2 portion of the study. The company expects to report Cohort 1 data

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Tue, 02 Jun 2026 07:00:00 -0400

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 --

-- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 --

BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201. The DMC recommended initiation of the Cohort 2 dose at 10 mg/kg, a dose escalation

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Tue, 02 Jun 2026 07:00:00 -0400

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 --

-- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 --

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:30:00 -0400

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units (“RSUs”) to three newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2026. The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

One-fourth of the RSUs will vest on the one-year anniversary of the vesting

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:30:00 -0400

One-fourth of the RSUs will vest on the one-year anniversary of the vesting

Form 4 Entrada Therapeutics, For: May 20 Filed by: Zeiher Bernhardt G

Thu, 21 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260521/26535971.html

Form 4 Entrada Therapeutics, For: May 20 Filed by: Zeiher Bernhardt G

Thu, 21 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260521/26535971.html

Form 8-K Entrada Therapeutics, For: May 18

Tue, 19 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260519/26516520.html

Form 8-K Entrada Therapeutics, For: May 18

Tue, 19 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260519/26516520.html